Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001033661 | SCV001196968 | likely pathogenic | Isovaleryl-CoA dehydrogenase deficiency | 2019-05-22 | criteria provided, single submitter | clinical testing | This variant is a gross deletion of the genomic region encompassing exons 10-12 of the IVD gene. The 5' boundary is likely confined to intron 9. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. This variant has not been reported in the literature in individuals with IVD-related conditions. This variant disrupts the p.Asp359 amino acid residue in IVD. Another variant that disrupts this residue has been determined to be pathogenic (Invitae). This suggests that this residue is clinically-significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |